Stock listing

Stuttgart:XE7C Cardiff Oncology, Inc. Aktie

German listing (Stuttgart) of Cardiff Oncology, Inc. · home listing NASDAQ:CRDF

Follow Cardiff Oncology, Inc. into a list and get an email when it puts out news.

Home listing price · NASDAQ:CRDF

$0.853 USD +0.014 (+1.6%)

Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:CRDF

Past year -56.5% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$0.832 – $0.904 USDNov 20, 2026
Volume
520,597 sharesNov 20, 2026
Market cap
$66.34M USDAt the close on Nov 20, 2026 · price × 77.80M shares outstanding
52-week range
$0.711 – $3.310 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$977,633 USDMedian day 504,800 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Cardiff Oncology, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:CRDF · Home$0.853 USD+0.014 (+1.6%)520,597$0.884$0.904$0.832$0.839Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:CRDF · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$0.853+0.014+1.6%$0.884$0.904$0.832520,597
$0.839-0.007-0.9%$0.840$0.876$0.813857,601
$0.846-0.001-0.2%$0.870$0.909$0.7901,974,553
$0.848+0.122+16.7%$0.795$0.937$0.79524,873,651
$0.726-0.002-0.2%$0.728$0.735$0.711204,773
$0.728-0.038-4.9%$0.750$0.762$0.720313,779
$0.765-0.029-3.7%$0.780$0.810$0.755333,991
$0.795-0.006-0.7%$0.780$0.810$0.760158,725
$0.801+0.005+0.7%$0.800$0.836$0.780397,137
$0.795+0.040+5.3%$0.798$0.798$0.760345,290
$0.755-0.114-13.1%$0.852$0.852$0.750708,031
$0.869+0.006+0.7%$0.867$0.900$0.844289,019
$0.863+0.019+2.2%$0.850$0.884$0.841224,953
$0.844-0.045-5.1%$0.898$0.910$0.833467,348
$0.890-0.022-2.5%$0.900$0.921$0.858126,854
$0.912+0.014+1.6%$0.902$0.950$0.900123,203
$0.898+0.022+2.6%$0.870$0.950$0.850280,536
$0.875+0.071+8.8%$0.820$0.890$0.781637,049
$0.804-0.103-11.4%$0.890$0.950$0.790866,649
$0.907-0.023-2.4%$0.920$0.940$0.885174,285
$0.930-0.010-1.1%$0.930$0.970$0.910228,700
$0.940+0.010+1.1%$0.950$0.970$0.920436,800
$0.930+0.040+4.5%$0.910$0.980$0.880595,200
$0.890-0.010-1.1%$0.920$0.930$0.880425,700
$0.900-0.070-7.2%$0.980$0.990$0.890515,500
$0.9700.0000.0%$0.950$1.000$0.950453,800
$0.970-0.040-4.0%$1.060$1.060$0.960412,900
$1.010-0.030-2.9%$1.040$1.050$1.000504,800
$1.040-0.040-3.7%$1.080$1.080$1.040377,200
$1.080+0.020+1.9%$1.060$1.110$1.060297,400
$1.060-0.030-2.8%$1.070$1.080$1.050541,000
$1.090+0.020+1.9%$1.070$1.130$1.070457,500
$1.070-0.070-6.1%$1.150$1.160$1.060384,200
$1.140+0.020+1.8%$1.100$1.150$1.090451,900
$1.120-0.060-5.1%$1.210$1.210$1.110628,300
$1.180-0.030-2.5%$1.220$1.220$1.160298,400
$1.210+0.040+3.4%$1.170$1.250$1.170564,600
$1.170-0.030-2.5%$1.190$1.240$1.160353,000
$1.200-0.040-3.2%$1.230$1.230$1.190377,400
$1.240-0.040-3.1%$1.300$1.300$1.230563,400
$1.280-0.030-2.3%$1.300$1.320$1.250596,300
$1.310-0.020-1.5%$1.320$1.340$1.280590,100
$1.330-0.040-2.9%$1.370$1.390$1.330518,500
$1.3700.0000.0%$1.390$1.410$1.360476,000
$1.370+0.070+5.4%$1.290$1.390$1.290737,800
$1.300-0.050-3.7%$1.360$1.380$1.2601,131,900
$1.350+0.010+0.7%$1.350$1.380$1.3101,852,300
$1.340+0.030+2.3%$1.420$1.510$1.3103,168,500
$1.310+0.100+8.3%$1.230$1.340$1.2202,100,100
$1.2100.0000.0%$1.210$1.220$1.170493,300
$1.210+0.160+15.2%$1.050$1.220$1.030744,600
$1.050-0.050-4.5%$1.080$1.080$1.020716,000
$1.100+0.010+0.9%$1.050$1.130$1.050708,200
$1.090+0.010+0.9%$1.080$1.100$1.070437,300
$1.080+0.020+1.9%$1.070$1.090$1.040375,500
$1.060+0.030+2.9%$1.040$1.090$1.010700,800
$1.030+0.040+4.0%$1.010$1.070$1.000838,800
$0.990+0.050+5.3%$0.940$1.010$0.900590,400
$0.940-0.050-5.1%$0.990$0.990$0.930527,300
$0.990+0.010+1.0%$0.980$1.000$0.980202,200
$0.980-0.040-3.9%$1.020$1.030$0.980274,300
$1.020+0.020+2.0%$1.000$1.070$0.980918,500
$1.000+0.120+13.6%$0.940$1.050$0.9301,685,300
$0.880-0.030-3.3%$0.930$0.930$0.880651,900
$0.910+0.010+1.1%$0.910$0.920$0.870554,200

Splits

4 splits since 2004 · NASDAQ:CRDF · every price before a split is adjusted for it

DayRatioWhat
1-for-6Consolidation
1-for-12Consolidation
1-for-6Consolidation
111-for-1Split
Ticker
Stuttgart:XE7C
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
Stuttgart
Currency
EUR

What changed lately

Latest news

All Cardiff Oncology, Inc. news

Cardiff Oncology, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
26 in the last 12 months · 124 in all · newest Nov 16, 2026 · oldest 2020
Calls
5 calls with a replay · 5 with a transcript · latest Feb 28, 2025
Decks
93 decks · latest October 2026

Where Cardiff Oncology, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:CRDF · Home listingNASDAQUnited StatesUSD
gettex:XE7CgettexGermanyEUR
LS Exchange:A2P4GULS ExchangeGermanyEUR
BOATS:CRDFBOATSUnited StatesUSD
Lang & Schwarz:A2P4GULang & SchwarzGermanyEUR
Frankfurt:XE7CFrankfurtGermanyEUR
Dusseldorf:XE7CDusseldorfGermanyEUR
Munich:XE7CMunichGermanyEUR
Stuttgart:XE7C · This pageStuttgartGermanyEUR
Tradegate:XE7CTradegateGermanyEUR

Valuation

EV/sales 58.7× against a median of 14.3×: 6th lowest of 7 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$32.82M USD
P/E
Loss
EV/sales
58.7×
EV/EBITDA
Negative EBITDA
Price/book
2.4×
Gross margin
Revenue too small
Operating margin
Revenue too small
Net margin
Revenue too small
Debt to equity
0.0×
Beta vs S&P 500
1.32

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Cardiff Oncology, Inc. · NASDAQ:CRDFUS$66.34MUS$32.82Mn/a58.7×n/a2.4×n/a0.0×1.32
ABIONYX Pharma SA · EURONEXT:ABNXUS$68.36MUS$55.53Mn/a12.4×n/a4.0×−136.6%1.0×n/a
Cingulate Inc. · NASDAQ:CINGUS$67.48MUS$1.21Bn/an/an/a3.3×n/a56.0×1.41
Energenesis Biomedical Co., Ltd. · TWSE:6657US$67.22MUS$47.02Mn/a203×n/a3.1×n/a0.0×n/a
MediciNova, Inc. · NASDAQ:MNOVUS$67.11MUS$38.45Mn/a41.1×n/a1.6×n/a0.0×0.56
Dicot Pharma AB · OMXSTO:DICOTUS$66.56MUS$44.51Mn/an/an/a3.0×n/a0.0×n/a
Polaryx Therapeutics, Inc. · NASDAQ:PLYXUS$66.30MUS$57.86Mn/an/an/a8.7×n/a0.0×1.66
PMV Pharmaceuticals, Inc. · NASDAQ:PMVPUS$66.17M−US$36.25Mn/an/an/a1.2×n/a0.0×1.43
Gossamer Bio, Inc. · NASDAQ:GOSSUS$65.57MUS$55.23Mn/a0.7×n/an/a−159.5%n/a1.56
Tenaya Therapeutics, Inc. · NASDAQ:TNYAUS$65.32MUS$1.38Mn/a0.5×n/a1.2×n/a0.1×2.42
Atara Biotherapeutics, Inc. · NASDAQ:ATRAUS$64.49MUS$64.14Mn/a16.2×n/an/a−368.6%n/a1.43
Median of the othersUS$66.43MUS$51.12M14.3×3.0×−159.5%0.0×1.43

Forecasts

2 strong buy · 1 buy · 3 hold · Analysts' consensus from EODHD, read Nov 14, 2026. Not 6ix's view and not investment advice.

Price target
6.28 USD · Analysts' mean
EPS, year to Dec 2026
-0.56 · 3 analysts
Revenue, year to Dec 2026
364.5K · 6 analysts

Team and board

OfficerRole
Mani MohindruPresident & Chief Executive Officer
Joshua MuntnerChief Financial Officer
Ajay AggarwalChief Operating Officer
Brigitte LindsayChief Accounting Officer
Leila AllandInterim Chief Medical Officer
Tod SmealChief Scientific Officer

Events

Calls

CallWhenStatus
Cardiff Oncology (NASDAQ:CRDF) Q4 2024 Earnings CallThu, Feb 27, 2025 · 8:30 PM ETReplay
Cardiff Oncology (NASDAQ:CRDF) Q2 2024 Earnings CallThu, Aug 08, 2024 · 4:30 PM ETReplay
Cardiff Oncology (NASDAQ:CRDF) Q1 2024 Earnings CallThu, May 02, 2024 · 4:30 PM ETReplay
Cardiff Oncology (NASDAQ:CRDF) Q4 2023 Earnings CallThu, Feb 29, 2024 · 4:30 PM ETReplay
Cardiff Oncology (NASDAQ:CRDF) Q3 2023 Earnings CallThu, Nov 02, 2023 · 4:30 PM ETReplay

Results days

QuarterResultsShare move
Q3 2026Nov 12, 2026 · Before open−4.9%
Q2 2026Aug 11, 2026 · After close−5.7%
Q1 2026May 14, 2026 · After close−3.5%
Q4 2025Feb 24, 2026 · After close+12.3%
Q3 2025Nov 6, 2025 · After close−2.7%
Q2 2025Jul 29, 2025 · After close−24.8%
Q1 2025May 8, 2025 · After close+1.1%
Q4 2024Feb 26, 2025 · After close−9.0%
Q3 2024Nov 7, 2024 · After close−24.7%
Q2 2024Aug 8, 2024 · After close+11.7%
All 20 quarters
QuarterResultsShare move
Q1 2024May 2, 2024 · After close−21.4%
Q4 2023Feb 29, 2024 · After close+64.4%
Q3 2023Nov 2, 2023 · After close−2.6%
Q2 2023Aug 9, 2023 · After close+8.4%
Q1 2023May 4, 2023 · After close−3.6%
Q4 2022Mar 2, 2023 · After close+1.7%
Q3 2022Nov 3, 2022 · After close0.0%
Q2 2022Aug 4, 2022 · After close+4.5%
Q1 2022May 5, 2022 · After close−1.5%
Q4 2021Feb 24, 2022 · After close+7.5%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (October 2026)Investor deck34 slidesOctober 2026
Technical Presentation (June 2026)Technical27 slidesJun 3, 2026
Investor Presentation (February 2026)Investor deck39 slidesFeb 25, 2026
Investor Presentation (January 2026)Investor deck68 slidesJanuary 2026
Investor Presentation (October 2025)Investor deck70 slidesOctober 2025
Investor Presentation (August 2025)Investor deck74 slidesAugust 2025
Technical Presentation (July 2025)Technical41 slidesJul 29, 2025
Corporate Update (July 2025)Corporate update41 slidesJul 29, 2025
Investor Presentation (June 2025)Investor deck92 slidesJune 2025
Investor Presentation (January 2025)Investor deck92 slidesJanuary 2025
Show 50 decks
DeckKindSlidesDate
Investor Presentation (January 2025)Investor deck92 slidesJanuary 2025
Technical Presentation (December 2024)Technical32 slidesDec 10, 2024
Investor Presentation (November 2024)Investor deck82 slidesNovember 2024
Investor Presentation (August 2024)Investor deck80 slidesAugust 2024
Investor Presentation (July 2024)Investor deck81 slidesJuly 2024
Investor Presentation (June 2024)Investor deck81 slidesJune 2024
Investor Presentation (May 2024)Investor deck79 slidesMay 2024
Investor Presentation (May 2024)Investor deck80 slidesMay 2024
Investor Presentation (March 2024)Investor deck80 slidesMarch 2024
Investor Presentation (March 2024)Investor deck81 slidesMarch 2024
Q4 2023 Earnings PresentationEarnings33 slidesFeb 29, 2024
Investor Presentation (February 2024)Investor deck63 slidesFebruary 2024
Investor Presentation (January 2024)Investor deck64 slidesJanuary 2024
Q3 2023 Earnings PresentationEarnings10 slidesNov 2, 2023
Investor Presentation (November 2023)Investor deck59 slidesNovember 2023
Q3 2023 Earnings PresentationEarnings10 slidesNov 1, 2023
Corporate Update (September 2023)Corporate update26 slidesSeptember 2023
Corporate Update (August 2023)Corporate update48 slidesAug 7, 2023
Investor Presentation (May 2023)Investor deck72 slidesMay 2023
Investor Presentation (March 2023)Investor deck72 slidesMarch 2023
Investor Presentation (January 2023)Investor deck72 slidesJanuary 2023
Investor Presentation (November 2022)Investor deck78 slidesNovember 2022
Investor Presentation (November 2022)Investor deck72 slidesNovember 2022
Corporate Update (September 2022)Corporate update66 slidesSep 12, 2022
Corporate Update (September 2022)Corporate update67 slidesSep 12, 2022
Investor Presentation (September 2022)Investor deck75 slidesSeptember 2022
Investor Presentation (August 2022)Investor deck66 slidesAugust 2022
Investor Presentation (June 2022)Investor deck66 slidesJune 2022
Investor Presentation (April 2022)Investor deck66 slidesApril 2022
Technical Presentation (January 2022)Technical37 slidesJan 18, 2022
Investor Presentation (November 2021)Investor deck51 slidesNovember 2021
Investor Presentation (October 2021)Investor deck48 slidesOctober 2021
Technical Presentation (September 2021)Technical45 slidesSep 8, 2021
Investor Presentation (August 2021)Investor deck48 slidesAugust 2021
Investor Presentation (July 2021)Investor deck49 slidesJuly 2021
Investor Presentation (June 2021)Investor deck49 slidesJun 1, 2021
Technical Presentation (April 2021)Technical53 slidesApr 12, 2021
Investor Presentation (March 2021)Investor deck48 slidesMarch 2021
Investor Presentation (February 2021)Investor deck48 slidesFebruary 2021
Investor Presentation (February 2021)Investor deck46 slidesFebruary 2021

This page holds 50 of 93 decks. Open Decks

Open Decks

Financings

RaiseDate
Registered direct offering of common stock and warrants
Closed: US$10M raised · US$1.05 a share · ½ warrant at US$1.31 for 66 months · H.C. Wainwright & Co.
Dealers: H.C. Wainwright & Co. (lead)
Buyers: Certain officers and directors (731,707 shares and accompanying warrants at $1.435 per share and accompanying warrant)
Insiders: Certain officers and directors are buying 731,707 shares and accompanying warrants at $1.435 per share and accompanying warrant
Use of proceeds: Working capital and general corporate purposes
Aug 11, 2026

Open Financings · Read by 6ix AI from the company's releases

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue593.0K683.0K488.0K386.0K359.0K366.0K244.6K378.3K505.4K381.1K
Cost of revenue904.0K404.0K398.0K200.0K500.0K11.2M0597.5K1.81M1.73M
Gross profit593.0K683.0K488.0K386.0K359.0K366.0K244.6K-219.0K-1.31M-1.35M
Research and development35.3M36.9M32.9M27.1M17.4M11.2M11.2M8.16M7.88M15.0M
Selling, general and administrative14.2M12.5M13.0M13.2M11.8M8.22M5.76M8.01M14.2M11.5M
Operating income-49.0M-48.7M-45.4M-39.9M-28.9M-19.1M-16.7M-17.1M-25.6M-40.1M
Depreciation and amortization364.0K404.0K398.0K236.0K451.0K466.0K494.2K859.5K1.25M1.07M
EBITDA-48.6M-48.2M-45.0M-39.7M-28.4M-18.6M-16.2M-16.2M-24.3M-39.1M
Interest expense1.58M02.00K025.4K1.03M1.67M
Income before tax-45.9M-45.4M-41.4M-38.7M-28.3M-19.3M-16.4M-16.5M-24.9M-39.2M
Income tax0000000000
Net income-45.9M-45.4M-41.4M-38.7M-28.3M-19.3M-16.4M-16.5M-24.9M-39.2M
Earnings per share, basic-0.69-0.95-0.93-0.89-0.73-1.08-2.80-8.26-51.76-1.30
Earnings per share, diluted-0.69-0.95-0.93-0.89-0.73-1.08-2.80-8.26-51.76-1.37

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents17.5M51.5M21.7M16.3M11.9M131.0M10.2M11.5M8.23M13.9M
Short-term investments40.8M40.3M53.2M88.9M128.9M0024.0M
Receivables182.0K773.0K288.0K771.0K535.0K320.0K203.5K167.8K77.1K100.5K
Inventory11
Current assets60.1M95.1M77.4M111.3M146.1M133.4M11.4M12.8M9.47M39.0M
Property, plant and equipment578.0K898.0K1.24M1.27M382.0K624.0K877.8K1.30M2.43M3.83M
Total assets61.9M97.2M81.6M116.2M149.5M134.7M13.1M14.2M12.3M44.0M
Accounts payable8.09M4.82M1.97M1.96M1.44M1.37M656.3K664.8K825.2K1.13M
Current liabilities16.4M13.4M10.4M7.81M6.56M6.12M4.78M2.92M3.95M7.80M
Long-term debt014.2M
Total debt832.0K1.52M2.15M2.71M3.12M869.0K1.73M01.33M2.36M
Total liabilities16.5M14.2M11.9M9.85M9.13M6.57M5.78M4.09M5.78M24.2M
Shareholders' equity45.4M82.9M69.7M106.3M140.4M128.2M7.31M10.1M6.51M19.8M
Shares outstanding68.3M66.5M44.7M44.7M42.0M36.8M8.59M3.83M733.2K30.7M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-37.9M-37.7M-30.9M-33.8M-23.0M-16.3M-13.3M-13.2M-23.3M-31.0M
Capital spending-44.0K-80.0K-582.0K-1.01M-205.0K-211.0K-67.6K-5.10K-101.1K-823.5K
Free cash flow-38.0M-37.8M-31.5M-34.8M-23.2M-16.5M-13.3M-13.2M-23.4M-31.9M
Cash from investing1.34M13.7M36.2M38.1M-131.4M-211.0K-67.6K22.8K24.0M-24.8M
Cash from financing2.58M53.8M075.0K35.5M137.3M12.1M16.4M-6.38M2.30M
Dividends paid-414.0K-24.0K-24.2M-24.2M-24.2M-24.2M-24.2M
Share buybacks75.0K35.5M24.2M12.1M32.1M25.1M24.2M
Change in cash-34.0M29.8M5.31M4.40M-119.0M120.8M-1.26M3.23M-5.69M-53.6M

Open Financials

Filings

FilingDateTypeFiled with
SCHEDULE 13G · Big-stake noticeNov 16, 2026Big-stake noticeSEC
8-K · Current reportNov 12, 2026ResultsSEC
10-Q · Quarterly reportNov 12, 2026Quarterly reportSEC
3 · Initial statement of ownershipOct 27, 2026Insider tradeSEC
8-K · Current reportOct 27, 2026Management or board changeSEC
8-K · Current reportOct 22, 2026Meeting outcomeSEC
8-K · Current reportSep 14, 2026Material contractSEC
DEFA14A · Additional proxy materialAug 26, 2026Meeting noticeSEC
DEF 14A · Proxy statementAug 26, 2026Meeting noticeSEC
PRE 14A · Preliminary proxy statementAug 14, 2026Meeting noticeSEC
Show 200 filings
FilingDateTypeFiled with
8-K · Current reportAug 11, 2026ResultsSEC
10-Q · Quarterly reportAug 11, 2026Quarterly reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedJul 27, 2026Big-stake noticeSEC
S-8 · Registration statement for employee plansJul 21, 2026Offer documentSEC
4 · Change in ownershipJul 16, 2026Insider tradeSEC
4 · Change in ownershipJul 16, 2026Insider tradeSEC
8-K · Current reportJul 16, 2026Material contractSEC
424B5 · ProspectusJul 16, 2026Offer documentSEC
4 · Change in ownershipJun 22, 2026Insider tradeSEC
4 · Change in ownershipJun 22, 2026Insider tradeSEC
4 · Change in ownershipJun 15, 2026Insider tradeSEC
4 · Change in ownershipJun 15, 2026Insider tradeSEC
4 · Change in ownershipJun 15, 2026Insider tradeSEC
4 · Change in ownershipJun 15, 2026Insider tradeSEC
4 · Change in ownershipJun 15, 2026Insider tradeSEC
8-K · Current reportJun 11, 2026Meeting outcomeSEC
8-K · Current reportJun 3, 2026Current reportSEC
8-K · Current reportMay 29, 2026Material contractSEC
8-K · Current reportMay 19, 2026Current reportSEC
8-K · Current reportMay 14, 2026ResultsSEC
10-Q · Quarterly reportMay 14, 2026Quarterly reportSEC
4 · Change in ownershipApr 28, 2026Insider tradeSEC
3 · Initial statement of ownershipApr 28, 2026Insider tradeSEC
DEFA14A · Additional proxy materialApr 23, 2026Meeting noticeSEC
DEF 14A · Proxy statementApr 23, 2026Meeting noticeSEC
ARS · Annual report to shareholdersApr 23, 2026Annual reportSEC
3 · Initial statement of ownershipApr 16, 2026Insider tradeSEC
4/A · Change in ownership, amendedApr 16, 2026Insider tradeSEC
4 · Change in ownershipApr 16, 2026Insider tradeSEC
4 · Change in ownershipApr 16, 2026Insider tradeSEC
8-K · Current reportApr 9, 2026Management or board changeSEC
4 · Change in ownershipApr 2, 2026Insider tradeSEC
8-K · Current reportApr 2, 2026Material contractSEC
SCHEDULE 13G/A · Big-stake notice, amendedMar 26, 2026Big-stake noticeSEC
8-K · Current reportFeb 25, 2026Current reportSEC
8-K · Current reportFeb 24, 2026Acquisition or disposalSEC
10-K · Annual reportFeb 24, 2026Annual reportSEC
4 · Change in ownershipFeb 18, 2026Insider tradeSEC
4 · Change in ownershipFeb 18, 2026Insider tradeSEC
3 · Initial statement of ownershipFeb 9, 2026Insider tradeSEC
8-K · Current reportJan 27, 2026Management or board changeSEC
8-K · Current reportNov 6, 2025ResultsSEC
10-Q · Quarterly reportNov 6, 2025Quarterly reportSEC
S-8 · Registration statement for employee plansAug 28, 2025Offer documentSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2025Big-stake noticeSEC
4 · Change in ownershipJul 31, 2025Insider tradeSEC
8-K · Current reportJul 29, 2025ResultsSEC
10-Q · Quarterly reportJul 29, 2025Quarterly reportSEC
SCHEDULE 13G · Big-stake noticeJul 29, 2025Big-stake noticeSEC
3 · Initial statement of ownershipJul 8, 2025Insider tradeSEC
4 · Change in ownershipJun 30, 2025Insider tradeSEC
4 · Change in ownershipJun 30, 2025Insider tradeSEC
4 · Change in ownershipJun 30, 2025Insider tradeSEC
4 · Change in ownershipJun 27, 2025Insider tradeSEC
4 · Change in ownershipJun 27, 2025Insider tradeSEC
4 · Change in ownershipJun 27, 2025Insider tradeSEC
8-K · Current reportJun 26, 2025Meeting outcomeSEC
8-K · Current reportJun 17, 2025Management or board changeSEC
EFFECT · Notice that a registration is effectiveMay 14, 2025Other filingsSEC
CORRESP · Letter to the SECMay 12, 2025Other filingsSEC
S-3/A · Registration statement, amendedMay 8, 2025Offer documentSEC
8-K · Current reportMay 8, 2025ResultsSEC
10-Q · Quarterly reportMay 8, 2025Quarterly reportSEC
DEFA14A · Additional proxy materialApr 30, 2025Meeting noticeSEC
ARS · Annual report to shareholdersApr 29, 2025Annual reportSEC
DEF 14A · Proxy statementApr 29, 2025Meeting noticeSEC
SCHEDULE 13G · Big-stake noticeApr 23, 2025Big-stake noticeSEC
4 · Change in ownershipMar 13, 2025Insider tradeSEC
4 · Change in ownershipMar 13, 2025Insider tradeSEC
4 · Change in ownershipMar 13, 2025Insider tradeSEC
4 · Change in ownershipMar 13, 2025Insider tradeSEC
UPLOAD · Letter from the SECMar 6, 2025Other filingsSEC
8-K · Current reportFeb 27, 2025ResultsSEC
S-3 · Registration statementFeb 27, 2025Offer documentSEC
10-K · Annual reportFeb 27, 2025Annual reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 12, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 5, 2025Big-stake noticeSEC
8-K · Current reportJan 6, 2025Current reportSEC
4 · Change in ownershipDec 18, 2024Insider tradeSEC
SCHEDULE 13G · Big-stake noticeDec 17, 2024Big-stake noticeSEC
4 · Change in ownershipDec 16, 2024Insider tradeSEC
4 · Change in ownershipDec 12, 2024Insider tradeSEC
424B5 · ProspectusDec 11, 2024Offer documentSEC
8-K · Current reportDec 10, 2024Material contractSEC
8-K · Current reportDec 10, 2024Current reportSEC
SC 13G · Big-stake noticeNov 8, 2024Big-stake noticeSEC
8-K · Current reportNov 7, 2024ResultsSEC
10-Q · Quarterly reportNov 7, 2024Quarterly reportSEC
SC 13G · Big-stake noticeOct 24, 2024Big-stake noticeSEC
8-K · Current reportAug 8, 2024ResultsSEC
10-Q · Quarterly reportAug 8, 2024Quarterly reportSEC
4 · Change in ownershipJul 1, 2024Insider tradeSEC
4 · Change in ownershipJul 1, 2024Insider tradeSEC
4 · Change in ownershipJul 1, 2024Insider tradeSEC
4 · Change in ownershipJul 1, 2024Insider tradeSEC
4 · Change in ownershipJul 1, 2024Insider tradeSEC
4 · Change in ownershipJul 1, 2024Insider tradeSEC
S-8 · Registration statement for employee plansJul 1, 2024Offer documentSEC
8-K · Current reportJun 20, 2024Meeting outcomeSEC
DEFA14A · Additional proxy materialJun 17, 2024Meeting noticeSEC
DEFA14A · Additional proxy materialJun 3, 2024Meeting noticeSEC
8-K · Current reportJun 3, 2024Current reportSEC
8-K · Current reportMay 2, 2024ResultsSEC
10-Q · Quarterly reportMay 2, 2024Quarterly reportSEC
DEFA14A · Additional proxy materialApr 25, 2024Meeting noticeSEC
ARS · Annual report to shareholdersApr 25, 2024Annual reportSEC
DEF 14A · Proxy statementApr 25, 2024Meeting noticeSEC
8-K · Current reportApr 8, 2024Current reportSEC
S-8 · Registration statement for employee plansMar 27, 2024Offer documentSEC
4 · Change in ownershipMar 7, 2024Insider tradeSEC
4 · Change in ownershipMar 7, 2024Insider tradeSEC
4 · Change in ownershipMar 7, 2024Insider tradeSEC
4 · Change in ownershipMar 7, 2024Insider tradeSEC
8-K · Current reportFeb 29, 2024ResultsSEC
10-K · Annual reportFeb 29, 2024Annual reportSEC
SC 13G/A · Big-stake notice, amendedFeb 6, 2024Big-stake noticeSEC
8-K · Current reportJan 8, 2024Current reportSEC
4 · Change in ownershipDec 19, 2023Insider tradeSEC
4 · Change in ownershipNov 14, 2023Insider tradeSEC
8-K · Current reportNov 2, 2023ResultsSEC
10-Q · Quarterly reportNov 2, 2023Quarterly reportSEC
8-K · Current reportSep 26, 2023Current reportSEC
8-K · Current reportAug 9, 2023ResultsSEC
10-Q · Quarterly reportAug 9, 2023Quarterly reportSEC
8-K · Current reportAug 7, 2023Current reportSEC
8-K · Current reportJul 24, 2023Current reportSEC
8-K · Current reportJun 20, 2023Current reportSEC
4 · Change in ownershipJun 20, 2023Insider tradeSEC
4 · Change in ownershipJun 20, 2023Insider tradeSEC
4 · Change in ownershipJun 20, 2023Insider tradeSEC
4 · Change in ownershipJun 20, 2023Insider tradeSEC
4 · Change in ownershipJun 20, 2023Insider tradeSEC
4 · Change in ownershipJun 20, 2023Insider tradeSEC
8-K · Current reportJun 15, 2023Meeting outcomeSEC
8-K · Current reportMay 4, 2023ResultsSEC
10-Q · Quarterly reportMay 4, 2023Quarterly reportSEC
ARS · Annual report to shareholdersApr 27, 2023Annual reportSEC
DEFA14A · Additional proxy materialApr 27, 2023Meeting noticeSEC
DEF 14A · Proxy statementApr 27, 2023Meeting noticeSEC
4 · Change in ownershipMar 16, 2023Insider tradeSEC
4 · Change in ownershipMar 16, 2023Insider tradeSEC
4 · Change in ownershipMar 16, 2023Insider tradeSEC
4 · Change in ownershipMar 16, 2023Insider tradeSEC
8-K · Current reportMar 10, 2023Current reportSEC
8-K · Current reportMar 2, 2023ResultsSEC
10-K · Annual reportMar 2, 2023Annual reportSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2023Big-stake noticeSEC
3 · Initial statement of ownershipFeb 9, 2023Insider tradeSEC
SC 13G/A · Big-stake notice, amendedFeb 9, 2023Big-stake noticeSEC
8-K · Current reportFeb 2, 2023Management or board changeSEC
SC 13G · Big-stake noticeJan 26, 2023Big-stake noticeSEC
SC 13D/A · Big-stake notice, amendedJan 26, 2023Big-stake noticeSEC
4 · Change in ownershipNov 29, 2022Insider tradeSEC
8-K · Current reportNov 3, 2022ResultsSEC
10-Q · Quarterly reportNov 3, 2022Quarterly reportSEC
4 · Change in ownershipOct 11, 2022Insider tradeSEC
8-K · Current reportOct 3, 2022Current reportSEC
4 · Change in ownershipSep 20, 2022Insider tradeSEC
4 · Change in ownershipSep 19, 2022Insider tradeSEC
4 · Change in ownershipSep 19, 2022Insider tradeSEC
4 · Change in ownershipSep 19, 2022Insider tradeSEC
8-K · Current reportSep 12, 2022Current reportSEC
8-K · Current reportSep 6, 2022Current reportSEC
8-K · Current reportAug 4, 2022ResultsSEC
10-Q · Quarterly reportAug 4, 2022Quarterly reportSEC
S-8 · Registration statement for employee plansJul 12, 2022Offer documentSEC
SC 13G · Big-stake noticeJul 8, 2022Big-stake noticeSEC
4 · Change in ownershipJul 6, 2022Insider tradeSEC
8-K/A · Current report, amendedJun 14, 2022Meeting outcomeSEC
4 · Change in ownershipJun 9, 2022Insider tradeSEC
8-K · Current reportJun 9, 2022Meeting outcomeSEC
8-K · Current reportMay 5, 2022ResultsSEC
10-Q · Quarterly reportMay 5, 2022Quarterly reportSEC
EFFECT · Notice that a registration is effectiveApr 26, 2022Other filingsSEC
CORRESP · Letter to the SECApr 21, 2022Other filingsSEC
DEFA14A · Additional proxy materialApr 15, 2022Meeting noticeSEC
DEF 14A · Proxy statementApr 14, 2022Meeting noticeSEC
UPLOAD · Letter from the SECApr 14, 2022Other filingsSEC
8-K · Current reportApr 12, 2022Management or board changeSEC
8-K · Current reportApr 8, 2022Current reportSEC
S-3 · Registration statementApr 5, 2022Offer documentSEC
4 · Change in ownershipMar 11, 2022Insider tradeSEC
4 · Change in ownershipMar 10, 2022Insider tradeSEC
4 · Change in ownershipMar 10, 2022Insider tradeSEC
4 · Change in ownershipMar 10, 2022Insider tradeSEC
4 · Change in ownershipMar 10, 2022Insider tradeSEC
4 · Change in ownershipMar 10, 2022Insider tradeSEC
4 · Change in ownershipMar 10, 2022Insider tradeSEC
4 · Change in ownershipMar 10, 2022Insider tradeSEC
4 · Change in ownershipMar 10, 2022Insider tradeSEC

This page holds 200 of 1,000 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Cardiff Oncology, Inc.’s releases · as of Nov 3, 2026

Common shares
77,795,249
Fully diluted
82,557,154

Fully diluted

LineSharesAs of
Common shares77,795,249Nov 3, 2026
Warrants4,761,905Jul 16, 2026

Warrants and options

Lot
Warrants · US$1.31 · expire about Jan 2032

Share count over time

CountShares
Nov 3, 202677,795,249

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
Vanguard3.37M4.3%US$4.08MSep 30, 2026
Laurion Capital Management LP3.1M4.0%US$3.75MSep 30, 2026
Pfizer Inc2.41M3.1%US$2.99MSep 30, 2026
Franklin Templeton1.21M1.5%US$1.05MSep 30, 2026
BlackRock936K1.2%US$1.13MSep 30, 2026
Blair William & Co917K1.2%US$1.11MSep 30, 2026
Geode Capital840K1.1%US$1.02MSep 30, 2026
GoalVest Advisory LLC687K0.88%US$832KSep 30, 2026
Gsa Capital Partners LLP538K0.69%US$650KSep 30, 2026
Balyasny Asset Management L.P.382K0.49%US$462KSep 30, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
State Street324K0.42%US$392KSep 30, 2026
Two Sigma322K0.41%US$389KSep 30, 2026
UBS300K0.39%US$363KSep 30, 2026
BNP Paribas228K0.29%US$276KSep 30, 2026
Susquehanna218K0.28%US$264KSep 30, 2026
X-Square Capital, LLC206K0.26%US$249KSep 30, 2026
Morgan Stanley181K0.23%US$219KSep 30, 2026
BNY162K0.21%US$196KSep 30, 2026
Goldman Sachs155K0.20%US$188KSep 30, 2026
Northern Trust153K0.20%US$185KSep 30, 2026
Millennium116K0.15%US$141KSep 30, 2026
AlphaCore Capital LLC108K0.14%US$131KSep 30, 2026
Marshall Wace, LLP108K0.14%US$131KSep 30, 2026
Jane Street78,2280.10%US$94,655Sep 30, 2026
Assenagon Asset Management S.A.67,2310.09%US$81,350Sep 30, 2026
XTX Topco Ltd62,6810.08%US$75,844Sep 30, 2026
Qube Research & Technologies Ltd59,3590.08%US$71,824Sep 30, 2026
AQR Capital Management LLC53,3760.07%US$64,585Sep 30, 2026
Renaissance Technologies51,8000.07%US$62,678Sep 30, 2026
Capstone Investment Advisors, LLC51,1900.07%US$61,940Sep 30, 2026
Elkhorn Partners Limited Partnership48,0000.06%US$58,080Sep 30, 2026
Creative Planning47,2870.06%US$57,217Sep 30, 2026
Glenview Trust Co43,1280.06%US$52,184Sep 30, 2026
HighTower Advisors, LLC34,2060.04%US$41,389Sep 30, 2026
Mariner, LLC26,0990.03%US$31,580Sep 30, 2026
Rockefeller Capital Management L.P.25,0000.03%US$30,250Sep 30, 2026
Tamar Securities, LLC23,7950.03%US$28,792Sep 30, 2026
RBC23,7210.03%US$29,000Sep 30, 2026
Dimensional23,3690.03%US$28,277Sep 30, 2026
Integrity Alliance, LLC.22,8600.03%US$27,661Sep 30, 2026
Post Resch Tallon Group Inc.22,5150.03%US$27,243Sep 30, 2026
R Squared Ltd22,2690.03%US$26,945Sep 30, 2026
Raymond James Financial Inc22,1720.03%US$26,828Sep 30, 2026
PFG Investments, LLC20,5010.03%US$24,806Sep 30, 2026
Baker Ellis Asset Management LLC20,0000.03%US$24,200Sep 30, 2026
Proactive Wealth Strategies LLC20,0000.03%US$24,200Sep 30, 2026
Brighton Jones LLC16,7410.02%US$20,257Sep 30, 2026
Capital Advisors Wealth Management, LLC15,5250.02%US$18,785Sep 30, 2026
Wells Fargo15,1300.02%US$18,307Sep 30, 2026
MAI Capital Management14,5760.02%US$17,637Sep 30, 2026

This page holds 50 of 73 holders. Open Shareholders

Funds

HolderSharesOf the companyValueAs of
Vanguard Total Stock Market Index Fund2.07M2.7%US$2.7MJun 30, 2026
Vanguard Extended Market Index Fund759K0.98%US$987KJun 30, 2026
Franklin Biotechnology Discovery Fund439K0.56%US$375KJul 31, 2026
Fidelity Extended Market Index Fund363K0.47%US$690KMay 31, 2026
Vanguard Russell 2000 Index Fund325K0.42%US$617KMay 31, 2026
iShares Micro-Cap ETF222K0.28%US$288KJun 30, 2026
Fidelity Total Market Index Fund114K0.15%US$217KMay 31, 2026
Fidelity Series Total Market Index Fund101K0.13%US$191KMay 31, 2026
Small Company Growth Portfolio72,0570.09%US$93,674Jun 30, 2026
Goldman Sachs Absolute Return Tracker Fund46,2420.06%US$60,115Jun 30, 2026
All 38 holders
HolderSharesOf the companyValueAs of
Vanguard Balanced Index Fund35,4180.05%US$46,043Jun 30, 2026
Fidelity Nasdaq Composite Index Fund34,6460.04%US$65,827May 31, 2026
Fidelity ZERO Total Market Index Fund30,5910.04%US$26,168Jul 31, 2026
Vanguard Russell 2000 Growth Index Fund28,2950.04%US$53,761May 31, 2026
Vanguard Institutional Total Stock Market Index Fund27,7270.04%US$36,045Jun 30, 2026
Vanguard Russell 2000 Value Index Fund25,0680.03%US$47,629May 31, 2026
Small Cap Index Fund23,8430.03%US$45,302May 31, 2026
Fidelity ZERO Extended Market Index Fund22,8920.03%US$19,582Jul 31, 2026
Bridge Builder Small/Mid Cap Value Fund16,9180.02%US$21,993Jun 30, 2026
1290 VT Micro Cap Portfolio15,0110.02%US$19,514Jun 30, 2026
Fidelity Flex Small Cap Index Fund13,5150.02%US$11,561Jul 31, 2026
Dimensional U.S. Core Equity 2 ETF7,385<0.01%US$6,317Jul 31, 2026
Siit Extended Market Index Fund7,300<0.01%US$13,870May 31, 2026
Victory Extended Market Index Fund7,233<0.01%US$6,187Jul 31, 2026
Bridge Builder Small/Mid Cap Growth Fund6,166<0.01%US$8,016Jun 30, 2026
VIP Extended Market Index Portfolio5,115<0.01%US$6,650Jun 30, 2026
Vanguard Russell 3000 Index Fund3,969<0.01%US$7,541May 31, 2026
ProShares Russell 2000 High Income ETF2,955<0.01%US$5,615May 31, 2026
ProShares UltraPro Russell20002,331<0.01%US$4,429May 31, 2026
ProShares Ultra Russell20002,310<0.01%US$4,389May 31, 2026
Destinations Small-Mid Cap Equity Fund1,935<0.01%US$3,677May 31, 2026
VIP Total Market Index Portfolio1,854<0.01%US$2,410Jun 30, 2026
Strategic Equity Allocation Trust1,791<0.01%US$2,328Jun 30, 2026
Morgan Stanley Pathway Small-Mid Cap Equity ETF1,563<0.01%US$2,970May 31, 2026
Total Stock Market Index Trust1,435<0.01%US$1,866Jun 30, 2026
Avantis U.S. Small Cap Equity ETF542<0.01%US$1,030May 31, 2026
ProShares Hedge Replication ETF59<0.01%US$112May 31, 2026
ProShares Russell 2000 Dynamic Buffer ETF18<0.01%US$34May 31, 2026

Insider trades

TradeTradeSharesPriceValueDate
Mohindru Mani
Director, Officer: Chief Executive Officer
Buy34,364USD 1.46US$50,171Jul 14, 2026
Pace Gary W
Director
Buy687,285USD 1.46US$1MJul 14, 2026
Pace Gary W
Director
Buy30,000USD 1.22US$36,600Jun 18, 2026
Mohindru Mani
Director, Officer: Chief Executive Officer
Buy24,703USD 1.21US$29,891Jun 18, 2026

Big stakes

StakeStakeSharesDateFiling
Highbridge Capital Management LLC5.80%4.76MSep 30, 2026Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Gary Jacob
Other companies: OKYO Pharma Limited (Chief Development Officer/Director · Since at least May 16, 2022); Virpax Pharmaceuticals, Inc. (Director · Feb 16, 2021 – Jan 1, 2022 · Past); Hepion Pharmaceuticals, Inc. (Director · Oct 7, 2013 – Feb 19, 2024 · Past); Callisto Pharmaceuticals Inc (Chief Executive Officer, Director · Jan 17, 2013 – Jan 17, 2013 · Past); Synergy Pharmaceuticals Inc (Executive Chairman, Director · Dec 6, 2011 – Jun 15, 2018 · Past)
Director · Jan 23, 2012 – Mar 23, 2021 · Past
Mani Mohindru
Other companies: CytomX Therapeutics, Inc. (Director · Since at least Dec 16, 2020); Tvardi Therapeutics, Inc. (CFO & Chief Strategy Officer · Aug 15, 2017 – Dec 2, 2019 · Past); Curis, Inc. (Chief Strategy Officer · Jan 19, 2016 – Feb 14, 2017 · Past)
President & Chief Executive Officer · Since at least Jun 10, 2021
Renee P. Tannenbaum
Other companies: ANI Pharmaceuticals, Inc. (Pharm.D., MBA · Since at least Mar 19, 2022); Zogenix Inc (Director · Feb 6, 2015 – Mar 7, 2022 · Past); Sharps Compliance Corp (Director · Feb 29, 2012 – Nov 21, 2013 · Past)
Director · Since at least Jun 10, 2021
Thomas Phd Adams
Other companies: Hepion Pharmaceuticals, Inc. (Director · Sep 20, 2016 – May 18, 2021 · Past); Synergy Pharmaceuticals Inc (Director · Jul 24, 2015 – Jul 3, 2018 · Past)
Executive Chairman, Director · Jan 4, 2016 – Jun 17, 2020 · Past
Brigitte Lindsay
Other companies: CytomX Therapeutics, Inc. (Chief Accounting Officer, ensuring continuity within the finance function · Jan 27, 2026 – Nov 5, 2026 · Past)
Chief Accounting Officer · Since at least Jan 27, 2026
Gary W Pace
Other companies: Pacira BioSciences, Inc. (Director · Jun 8, 2022 – Mar 6, 2024 · Past)
Director · Since at least Sep 15, 2022
Paul Billings
Other companies: MetaStat Inc (Director · May 24, 2017 – Oct 11, 2017 · Past)
Director · Oct 30, 2013 – Jan 23, 2018 · Past
Roger Sidhu
Other companies: Ernexa Therapeutics Inc. (Chief Medical Officer · Sep 20, 2021 – Sep 20, 2022 · Past)
Chief Medical Officer · Since at least Jun 16, 2025
Steve Zaniboni
Other companies: Sorrento Therapeutics, Inc. (Director · Nov 29, 2010 – Nov 29, 2010 · Past)
Former CFO · Jan 23, 2012 – Apr 21, 2016 · Past
William J Welch
Other companies: Sequenom Inc (President & CEO · Feb 8, 2011 – Jun 10, 2015 · Past)
Chief Executive Officer, Director · Apr 25, 2016 – Jan 30, 2018 · Past
All 16 people
PersonSeat
Ajay AggarwalChief Operating Officer · Since at least Apr 9, 2026
James O ArmitageDirector · Since at least Jun 27, 2024
Joshua MuntnerChief Financial Officer · Since at least Apr 6, 2026
Katherine L RuffnerChief Medical Officer · Jul 6, 2021 – Mar 9, 2022 · Past
Leila AllandInterim Chief Medical Officer · Since at least Oct 27, 2026
Tod SmealChief Scientific Officer · Since at least Apr 17, 2026

Open People

Log in to ask 6ix AI your own questions about Cardiff Oncology, Inc.